Accessibility StatementSkip Navigation NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Fortinet, Inc. ("Fortinet" or "the Company") (NASDAQ: FTNT) and certain of its officers. Class Definition A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/FTNT. or you may contact P ...

Accessibility StatementSkip Navigation NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against RCI Hospitality Holdings, Inc. ("RCI" or "the Company") (NASDAQ: RICK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities th ...

Core Viewpoint - Semler Scientific, Inc. is facing a class action lawsuit due to alleged securities fraud related to undisclosed investigations by the U.S. Department of Justice regarding the QuantaFlo device reimbursement claims [3][5]. Group 1: Company Background - Semler filed its Form 10-K with the SEC on February 28, 2025, revealing an initial civil investigative demand from the DOJ dating back to July 2017 [3]. - The company has received multiple requests for information from the DOJ over the years, with the latest being in April 2023 [3]. Group 2: Financial Impact - Following the disclosure of the DOJ investigation, Semler's share price dropped by $4.03, approximately 9.39%, from $42.92 to $38.89 between February 28 and March 3, 2025 [3]. - After announcing a settlement agreement of $29.75 million on April 15, 2025, Semler's shares fell by $3.40, or about 9.9%, from $34.40 to $31.00 the following day [4]. Group 3: Lawsuit Details - The class action lawsuit is on behalf of investors who purchased Semler securities from March 10, 2021, to April 15, 2025, alleging that the company made false or misleading statements regarding the DOJ investigation [5]. - The lawsuit claims that the company failed to disclose material information about the investigation, leading to investor damages when the truth was revealed [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Cytokinetics, Inc. common stock during the specified Class Period, alleging misleading statements regarding the New Drug Application for aficamten [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Cytokinetics, Inc. and covers stock purchases made between December 27, 2023, and May 6, 2025 [1]. - The lawsuit claims that Cytokinetics made false statements about the expected approval timeline for aficamten, specifically regarding the FDA's approval process and the failure to disclose risks related to the Risk Evaluation and Mitigation Strategy [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting Rosen Law Firm directly for more information [3][6]. - A lead plaintiff must be appointed by November 17, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - RCI Hospitality Holdings, Inc. is under investigation for potential securities fraud and unlawful business practices following allegations of bribery involving tax auditors, leading to a significant drop in stock price [1][3]. Group 1: Investigation and Allegations - Pomerantz LLP is investigating claims on behalf of RCI investors regarding possible securities fraud or unlawful business practices by the company and its executives [1]. - The New York Attorney General's office indicted certain top executives of RCI, alleging they bribed an auditor to evade over $8 million in sales taxes from 2010 to 2024 [3]. Group 2: Market Reaction - Following the news of the indictment, RCI's stock price fell by $25.80 per share, representing a decline of 24.83%, closing at $25.80 per share on September 17, 2025 [3].

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate (“Cytokinetics” or the “Company”) (NASDAQ: CYTK). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Cytokinetics a ...

Core Viewpoint - Law Offices of Frank R. Cruz is encouraging investors of Jasper Therapeutics, Inc. (JSPR) to inquire about a potential securities fraud class action [1] Group 1 - The law firm is actively seeking investors who may have been affected by the alleged securities fraud involving Jasper Therapeutics [1] - The announcement indicates a growing concern regarding the company's practices and potential legal implications for investors [1] - This action reflects broader issues within the biotechnology sector, where companies may face scrutiny over their financial disclosures and operational transparency [1]

Accessibility StatementSkip Navigation BENSALEM, Pa., Sept. 23, 2025 /PRNewswire/ -- The Law Offices of Howard G. Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:Â LNTH). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN LANTHEUS HOLDINGS, INC. (LNTH), CONTACT THE LAW OFFICES OF HOWARD G. SMITHÂ BEFORE NOVEMBER 10, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ON ...

Core Viewpoint - Investors in Savara Inc. have the opportunity to lead a securities fraud class action lawsuit due to undisclosed information regarding the company's regulatory submissions and prospects [1][2]. Summary by Relevant Sections Lawsuit Details - The lawsuit alleges that from March 7, 2024, to May 23, 2025, Savara's defendants failed to disclose critical information about the MOLBREEVI Biologics License Application (BLA), including insufficient details on its chemistry, manufacturing, and controls [2]. - It is claimed that the FDA was unlikely to approve the MOLBREEVI BLA in its current form, which would delay Savara's submission timeline and increase the need for additional capital [2]. - The lawsuit asserts that the defendants' positive statements regarding the company's business and prospects were materially misleading and lacked a reasonable basis during the relevant period [2]. Participation Information - Investors who suffered losses related to Savara are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for November 7, 2025 [2]. - Interested parties can contact The Law Offices of Frank R. Cruz for more information or to participate in the class action [3][4].

NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. ("Nutex Health Inc." or the "Company") (NASDAQ: NUTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/nutex- ...